8.64 +0.20 (2.37%)
Pre-market: 7:18AM EDT
|Bid||8.75 x 2200|
|Ask||8.84 x 800|
|Day's range||7.82 - 8.68|
|52-week range||1.92 - 19.36|
|Beta (5Y monthly)||0.76|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||10.43|
Seemingly hopeful news came out of New York Monday, which could be nearing its apex of the novel coronavirus crisis, while markets opened higher to start a week that could see other metro areas surge in cases and deaths.
NEW ORLEANS, April 06, 2020 -- ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:.
Hagens Berman urges investors in Inovio Pharmaceuticals, Inc. (INO) who have suffered significant losses to submit their losses now. The complaint alleges that Defendants made misleading statements about Inovio’s development of a purported vaccine for the novel coronavirus. Specifically, in a Feb. 14, 2020 televised interview, Inovio CEO J. Joseph Kim stated that Inovio had developed a COVID-19 vaccine “in a matter of about three hours once we had the DNA sequence from the virus.”
The law firm of Kessler Topaz Meltzer & Check, LLP reminds Inovio Pharmaceuticals, Inc. (NASDAQ: INO) (“Inovio”) investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Eastern District of Pennsylvania against Inovio on behalf of those who purchased or otherwise acquired Inovio common stock between February 14, 2020 and March 9, 2020, inclusive (the “Class Period”). Important Deadline Reminder: Investors who purchased or otherwise acquired Inovio common stock during the Class Period may, no later than May 12, 2020, seek to be appointed as a lead plaintiff representative of the class. According to the complaint, Inovio is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure and/or protect people from infectious diseases.
NEW ORLEANS, April 03, 2020 -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending.
Shareholder rights law firm Robbins LLP reminds investors that a purchaser of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between February 14, 2020 and March 9, 2020. Inovio is a late-stage biotechnology Company that focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines.
NEW YORK, April 01, 2020 -- Pomerantz LLP is investigating claims on behalf of investors of Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO). Such.
CEDARHURST, N.Y., March 31, 2020 -- The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies..
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Inovio Pharmaceuticals, Inc. ("Inovio" or the "Company") (NASDAQ:INO) of the May 12, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements about Inovio’s development of a purported vaccine for the novel coronavirus, artificially inflating the company’s share price and resulting in significant investor losses.
The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron, Sanofi, Moderna and Inovio Pharmaceuticals
Robbins Geller Rudman & Dowd LLP announces that a securities class action lawsuit has been filed in the Eastern District of Pennsylvania on behalf of purchasers of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) common stock between February 14, 2020 and March 9, 2020 (the "Class Period"). The case is captioned McDermid v. Inovio Pharmaceuticals, Inc., No. 20-cv-01402, and is assigned to Judge Gerald J. Pappert. The Inovio Pharmaceuticals securities class action lawsuit charges Inovio Pharmaceuticals and its Chief Executive Officer ("CEO") with violations of the Securities Exchange Act of 1934.
Novavax's (NVAX) NanoFlu, the influenza vaccine candidate for adults aged 65 years and older, meets all the primary and secondary endpoints in late-stage study. Shares rise.
Fast-track approval for coronavirus drug trials is encouraging drug developers. Here are four stocks that can make the most of this phase.
Aytu BioScience (AYTU) expands the right to distribute and commercialize the COVID-19 IgG/IgM rapid test across the United States, Canada and Mexico. Stock jumps.
PHILADELPHIA, March 24, 2020 -- Kaskela Law LLC announces that a shareholder class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. (“Inovio” or the.